ARIDOL KIT
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
12-06-2019
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
MANNITOL; MANNITOL; MANNITOL; MANNITOL
から入手可能:
PHARMAXIS LTD
ATCコード:
V04CX
INN（国際名）:
OTHER DIAGNOSTIC AGENTS
投薬量:
5MG; 10MG; 20MG; 40MG
医薬品形態:
KIT
構図:
MANNITOL 5MG; MANNITOL 10MG; MANNITOL 20MG; MANNITOL 40MG
投与経路:
INHALATION
パッケージ内のユニット:
15G/50G
処方タイプ:
Prescription Recommended
治療領域:
DIAGNOSTIC AGENTS
製品概要:
Active ingredient group (AIG) number: 0461510001; AHFS:
認証ステータス:
APPROVED
承認日:
2019-06-13
製品の特徴
_Pr_
_Aridol_
®
_ Product Monograph _
_Page 1 of 29_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ARIDOL
®
Mannitol Inhalation Powder
Inhalation Powder, Capsules of 0 mg, 5 mg, 10 mg, 20 mg or 40 mg, Oral
Inhalation
Diagnostic Agent to Assess Bronchial Hyperresponsiveness
ATC Code: V04CX
Pharmaxis Ltd
20 Rodborough Rd
Frenchs Forest ,2086
Australia
Imported and Distributed by:
Methapharm Inc
81 Sinclair Boulevard
Brantford, ON N3S 7X6
Canada
Date of Initial Approval:
June 12, 2019
Submission Control No: 217446
_Pr_
_Aridol_
®
_ Product Monograph _
_Page 2 of 29_
TABLE OF CONTENTS
PR
ARIDOL
® ................................................................................................................................
1
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................... 4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
...................................................... 4
4
DOSAGE AND ADMINISTRATION
...............................................................................
5
4.1
Dosing Considerations
............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
........................................................ 5
4.3
Administration
.........................................................................................................
5
5
OVERDOSAGE
...........................................................................................................
13
6
DOSAGE
完全なドキュメントを読む
